



## **Derek Smith appointed Global CEO of SomnoMed**

**19<sup>th</sup> July 2016**, The board of SomnoMed Limited (ASX:SOM) is pleased to announce the appointment of Derek Smith as new global CEO from 1 September 2016. The appointment followed an extensive search and evaluation of candidates by executive search firm Spencer Stuart in New York. Dr. Peter Neustadt, the current global CEO and Executive Chairman of SomnoMed Limited will return to his previous role of non-executive Chairman after transferring global executive responsibilities during the month of September.

Derek has held senior positions with Respironics, Inc. since 2005. He had an outstanding career over the years in sales and marketing of various US and international healthcare companies, which included E Merck, Datex Ohmeda and McKesson. In 2005 Derek accepted the appointment as President of Respironics Hospital Group, being part of the top management team of the leading US CPAP maker. Following the takeover of Respironics in 2008 by global Philips corporation, Derek held positions as Senior Vice President of Respiratory and Perinatal Care for Philips Healthcare, as Senior Vice President of Therapeutic Care and finally as CEO Hospital to Home Business division at Philips Healthcare.

"I am very pleased that Derek accepted the position as global CEO for SomnoMed. His background is perfectly fitted to the role of managing SomnoMed. His achievements in various health care companies but especially in Respironics and Philips gave our board great confidence that Derek will be able to implement the global strategy of SomnoMed and continue the exciting build up of our global business," said Dr. Neustadt.

"Over the last four years, since I took over as global CEO, we have broadened our product line, expanded geographically and consistently built a global leadership position in the treatment of obstructive sleep apnea using SomnoDent<sup>®</sup> devices. Now with over 90% of our business being outside Australia, predominantly in the US and Europe, SomnoMed needs an executive leader based in the US. As a senior executive with extensive global experience and a proven track record with larger companies, Derek is ideally suited to continue this work and take SomnoMed to the next level as a global medical device company. Derek will have my personal and the board's full support," commented Dr. Neustadt.

Mr Smith was born and educated in the United Kingdom, receiving a BSc (Hons) Biochemistry from Newcastle University (England). After working for E-Merck and Ohmeda in Europe he transferred to the USA in the early eighties and since that time has worked for US based companies.

Derek will be based in Denver, Colorado and visit Australia regularly. Shareholders will have the opportunity to meet the new global CEO at the annual shareholders' meeting in November.

**Contact:** Dr. Peter Neustadt – Executive Chairman and CEO, SomnoMed Limited

Ph +61 2 9467 0400 or +61 (0) 414 566 592 - mobile

### **About SomnoMed**

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent<sup>®</sup> becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent<sup>®</sup> is the most comfortable and effective design and treatment solution for over 250,000 patients in 27 countries.

For additional information, visit SomnoMed at <http://www.somnomed.com.au>